The abstract is read at the publisher; the summary is JClub's.
In EGFR-mutated, MET-amplified advanced NSCLC after EGFR-TKI progression, dalmelitinib plus aumolertinib improved median progression-free survival to 6.2 months versus 4.4 months with chemotherapy (HR 0.60).
- Why it matters: MET amplification is a common acquired resistance mechanism after EGFR-TKI therapy, but precision options are limited, especially after third-generation EGFR-TKI treatment.
- What they did: In a randomized open-label phase 3 trial (NCT06110663) of 314 patients, investigators compared dalmelitinib-aumolertinib against platinum-based chemotherapy, with MET amplification defined by FISH (mean MET copy number ≥5 or MET/CEP7 ratio ≥2).
- The result: The combination increased objective response rate to 59.6% versus 38.6% and extended duration of response to 9.7 versus 4.4 months, with grade ≥3 adverse events in 50.0% versus 51.0%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.